Last reviewed · How we verify
low molecule heparin
low molecule heparin is a Anticoagulant Small molecule drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University. It is currently FDA-approved for Prevention and treatment of deep vein thrombosis, Prevention and treatment of pulmonary embolism, Acute coronary syndrome.
Low molecular weight heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa.
Low molecular weight heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa. Used for Prevention and treatment of deep vein thrombosis, Prevention and treatment of pulmonary embolism, Acute coronary syndrome.
At a glance
| Generic name | low molecule heparin |
|---|---|
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | Anticoagulant |
| Target | Antithrombin III (indirect); Factor Xa and Factor IIa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Low molecular weight heparin (LMWH) is derived from unfractionated heparin through chemical or enzymatic depolymerization, resulting in smaller chain lengths. It binds to antithrombin III and potentiates its inhibition of factor Xa more selectively than factor IIa, providing predictable pharmacokinetics and a more favorable bleeding profile compared to unfractionated heparin. LMWH is used for both treatment and prevention of thrombotic events.
Approved indications
- Prevention and treatment of deep vein thrombosis
- Prevention and treatment of pulmonary embolism
- Acute coronary syndrome
- Thromboprophylaxis in surgical patients
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
Key clinical trials
- COOLEY- Study: ACute on ChrOnic Liver FailurE Using the CYtosorb Device (NA)
- Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement (PHASE2)
- Prophylactic Anticoagulation for Catheter-related Thrombosis (PHASE4)
- Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low molecule heparin CI brief — competitive landscape report
- low molecule heparin updates RSS · CI watch RSS
- Second Affiliated Hospital, School of Medicine, Zhejiang University portfolio CI
Frequently asked questions about low molecule heparin
What is low molecule heparin?
How does low molecule heparin work?
What is low molecule heparin used for?
Who makes low molecule heparin?
What drug class is low molecule heparin in?
What development phase is low molecule heparin in?
What are the side effects of low molecule heparin?
What does low molecule heparin target?
Related
- Drug class: All Anticoagulant drugs
- Target: All drugs targeting Antithrombin III (indirect); Factor Xa and Factor IIa
- Manufacturer: Second Affiliated Hospital, School of Medicine, Zhejiang University — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Prevention and treatment of deep vein thrombosis
- Indication: Drugs for Prevention and treatment of pulmonary embolism
- Indication: Drugs for Acute coronary syndrome
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing